This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also ...

Weight loss injections have been conditionally recommended for treating obesity by the World Health Organization (WHO) for the first time.

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non ...

More than half of people prescribed weight-loss drugs Saxenda and Wegovy over the past decade ended their treatment too early to realize meaningful health benefits, according to a study by a major U.S ...

There are three main types of injectable weight loss drugs approved by the Food and Drug Administration (FDA): semaglutide, liraglutide and tirzepatide. These are administered either daily or weekly ...

The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva Pharmaceuticals announced Thursday. The generic form of liraglutide (Saxenda) is ...

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

After Novo Nordisk’s popular obesity medicine Wegovy went into short supply, people turned to the company’s first-generation weight-loss drug, Saxenda, for treatment. Now, the company is struggling to ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...